Several pharmacological compounds have been or are currently being evaluated in FA patients, including antioxidants (e.g. idebenone), iron chelators (e.g. deferiprone) or compounds that could increase frataxin protein levels (e.g. histone deacetylase inhibitors or erythropoeitin) (reviewed in Aranca et al., 2016). The gene discussed is FXN; the disease is Friedreich ataxia.